Antimalarial medication multi-drug resistant "P. falciparum". It is a very potent blood schizonticide with a long half-life. It is thought to act by forming toxic heme complexes that damage parasitic food vacuoles. Mefloquine is effective in prophylaxis and for acute therapy. It is now used solely for the prevention of resistant strains of "P. falciparum" (usually combined with Artesunate) despite being effective against "P. vivax", "P. ovale" and "P. marlariae". Chloroquine/proguanil or sulfa drug-pyrimethamine combinations should be used in all other plasmodia infections. The major commercial manufacturer of mefloquine-based malaria treatment is Roche Pharmaceuticals, which markets the drug under the trade name
International Association for the Treatment of Sexual Offenders changes as well. A "one size fits all" approach can not be used because youth who have committed sexual crimes are a diverse population, meaning they are all different in numerous ways. Treatment response to sexual abuse by juveniles is based on relapsed prevention, offense cycle, and presumption of sexual dividends. Some research coming out suggests that the successful treatments are those which include community-based and involve supportive adults in the youth's life. Something to keep in mind is label the behavior of the youth, not their identity, because it helps to make sure that youths do not develop a